Candel Therapeutics, Inc. revenue

Revenue history

AnnualQuarterly

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Candel Therapeutics, Inc.: revenue history, annual

Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	125	125	125
Growth on the year before	—	0.0%	0.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Candel Therapeutics, Inc.	$124,000	0.0%	—
Ibio, Inc.	$100,000	-75.0%	-62.4%
Lisata Therapeutics, Inc.	$100,000	-90.7%	—
Celldex Therapeutics, Inc.	$158,000	-97.3%	-63.5%
AIM Immunotech Inc.	$95,000	-21.5%	-17.3%
Clene Inc.	$197,000	-31.1%	-36.9%

Compare with peers

• Ibio, Inc. revenue
• Lisata Therapeutics, Inc. revenue
• Celldex Therapeutics, Inc. revenue
• AIM Immunotech Inc. revenue
• Clene Inc. revenue

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Candel Therapeutics, Inc.